CommercialCoverageMedium impact
08.01.36e, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)
Independence Blue Cross·Neurology, Pediatrics·Pharmacy
Effective date
Oct 2, 2024
We identified it
Jun 19, 2026
Summary
The Spinal Muscular Atrophy therapy policy for Spinraza and Zolgensma medications has been reissued with updates effective October 2, 2024. This pharmacy policy affects coverage and potentially prior authorization requirements for these specialized SMA treatments.
Action Required
Immediately: Billing team should review the updated policy details at the source URL to identify any changes to prior authorization requirements, coverage criteria, or billing procedures for Spinraza and Zolgensma treatments. Update billing protocols accordingly for any SMA patients receiving these therapies.